Novo Nordisk (NYSE: NVO) -- the original Ozempic stock -- is getting a boost from a Financial Times report this morning highlighting positive results from two weight loss trials using increased dosages of semaglutide (the active ingredient in Ozempic).

Novo Nordisk stock is responding positively to the news, up 2.1% through 10:55 a.m. ET.

Image source: Getty Images.

Continue reading

Source Fool.com